Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DESTINY-PanTumor01: Trastuzumab deruxtecan in HER2-mutant unresectable/metastatic solid tumors
jRCT2031210132Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Aug 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab deruxtecan in Nonhematologic neoplasms, sponsored by Daiichi Sankyo Co., Ltd. Started Aug 2021; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031210132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210132.